Phase 4 Bladder Cancer Trial, Recruiting NCT06215976 Sponsor: Cairo University Condition: Bladder Cancer
Back to Bladder Cancer

Phase 4 Bladder Cancer Trial, Recruiting

NCT06215976
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 65 years old who do not have diabetes
  • People who have been diagnosed with bladder cancer and have not yet received any chemotherapy treatment
  • People whose kidneys are functioning well, based on a specific kidney function measurement being above a set level (confirm with trial site)

Who may not be able to join:

  • People who have a history of a condition called lactic acidosis (a dangerous build-up of acid in the blood)
  • People who are currently taking certain medications that can harm the kidneys, such as frusemide, anti-inflammatory painkillers (like ibuprofen), or certain antibiotics (such as aminoglycosides or vancomycin)
  • People whose kidney function is unstable or has suddenly gotten worse in a short period of time
  • People who have heart failure, have recently had a heart attack, or have experienced a serious collapse of heart function
  • People who have a severe infection or blood poisoning (sepsis), including any infection serious enough to require a hospital stay or the need for oxygen support or other emergency measures
  • People who drink alcohol
  • People who have serious breathing problems or respiratory failure
  • People who have severe liver disease (at an advanced stage known as Child-Pugh class C)
  • People whose cancer has spread to other parts of the body (metastasis)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Samar Farid, faculty of pharmacy Cairo University

Phone: 0201094164048

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
1 June 2023
Est. completion
1 June 2024

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

serum creatinine (SCr); Human Neutrophil gelatinase-associated lipocalin (NGAL); Cystatin C; Estimated glomerular filtration rate (eGFR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov